The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Antibody fragments: Hope and hype
Open accessAbstract
The antibody molecule is modular and separate domains can be extracted through biochemical or genetic means. It is clear from review of the literature that a wave of novel, antigen-specific molecular forms may soon enter clinical evaluation. This report examines the developmental histories of therapeutics derived from antigen-specific fragments of antibodies produced by recombinant processes. Three general types of fragments were observed, antigen-binding fragments (Fab), single chain variable fragments (scFv) and "third generation" (3G), each representing a successive wave of antibody fragment technology. In parallel, drug developers have explored multi-specificity and conjugation with exogenous functional moieties in all three fragment types. Despite high hopes and an active pipeline, enthusiasm for differentiating performance of fragments should, perhaps, be tempered as there are yet few data that suggest these molecules have distinct clinical properties due only to their size.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Engineered antibody fragments and the rise of single domains
Holliger, P., & Hudson, P. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1142 · Cited by 1,931
Single-Chain Antigen-Binding Proteins
Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S.-M., Lee, T., Pope, S. H., Riordan, G. S., & Whitlow, M. (1988) · Science · doi:10.1126/science.3140379 · Cited by 1,502
Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.
Yokota, T., Milenic, D. E., Whitlow, M. D., & Schlom, J. (1992) · PubMed · Cited by 819
Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors.
Jain, R. K. (1990) · PubMed · Cited by 574
Hybrid hybridomas and their use in immunohistochemistry
Milstein, C., & Cuello, A. C. (1983) · Nature · doi:10.1038/305537a0 · Cited by 517
Development trends for monoclonal antibody cancer therapeutics
Reichert, J. M., & Valge-Archer, V. E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2241 · Cited by 389
Offner, S., Hofmeister, R., Romaniuk, A., Kufer, P., & Baeuerle, P. A. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.03.007 · Cited by 365
Dreier, T., Lorenczewski, G., Brandl, C., Hoffmann, P., Syring, U., Hanakam, F., Kufer, P., Riethmuller, G., Bargou, R., & Baeuerle, P. A. (2002) · International Journal of Cancer · doi:10.1002/ijc.10557 · Cited by 348
Domain antibodies: proteins for therapy
Holt, L. J., Herring, C., Jespers, L. S., Woolven, B. P., & Tomlinson, I. M. (2003) · Trends in Biotechnology · doi:10.1016/j.tibtech.2003.08.007 · Cited by 345
Bispecific antibodies for cancer therapy: The light at the end of the tunnel?
Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336
Hu, S., Shively, L., Raubitschek, A. A., Sherman, M. A., Williams, L. E., Wong, J. Y., Shively, J. E., & Wu, A. M. (1996) · PubMed · Cited by 330
Development trends for therapeutic antibody fragments
Nelson, A. L., & Reichert, J. M. (2009) · Nature Biotechnology · doi:10.1038/nbt0409-331 · Cited by 305
Self-citationMonoclonal Antibodies as Innovative Therapeutics
Reichert, J. (2008) · Current Pharmaceutical Biotechnology · doi:10.2174/138920108786786358 · Cited by 265
Zeidler, R., Reisbach, G., Wollenberg, B., Lang, S., Chaubal, S., Schmitt, B., & Lindhofer, H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1246 · Cited by 204
Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs
Holt, L. J., Basran, A., Jones, K., Chorlton, J., Jespers, L. S., Brewis, N. D., & Tomlinson, I. M. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzm067 · Cited by 193
PEGylation: An Approach for Drug Delivery. A Review
Jain, A., & Jain, S. (2008) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v25.i5.10 · Cited by 186
Construction, expression, and activity of a bivalent bispecific single-chain antibody.
Mallender, W. D., & Voss, E. W. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42334-9 · Cited by 120
Cumber, A. J., Ward, E. S., Winter, G., Parnell, G. D., & Wawrzynczak, E. J. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.1.120 · Cited by 85
Kurucz, I., Titus, J. A., Jost, C. R., & Segal, D. M. (1995) · Molecular Immunology · doi:10.1016/0161-5890(95)00105-0 · Cited by 74
Antibody engineering: facing new challenges in cancer therapy
Sanz, L., Cuesta, Á. M., Compte, M., & Álvarez‐Vallina, L. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00135.x · Cited by 63
Hayden, M. S., Linsley, P. S., Gayle, M. A., Bajorath, J., Brady, W., Norris, N. A., Fell, H. P., Ledbetter, J. A., & Gilliland, L. K. (1994) · PubMed · Cited by 53
Cited by
Dugel, P. U., Koh, A., Ogura, Y., Jaffe, G. J., Schmidt-Erfurth, U., Brown, D. M., Gomes, A. V., Warburton, J., Weichselberger, A., & Holz, F. G. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.04.017 · Cited by 931
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546
Fc‐fusion proteins: new developments and future perspectives
Czajkowsky, D. M., Hu, J., Shao, Z., & Pleass, R. J. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201379 · Cited by 476
Nanobodies as therapeutics: big opportunities for small antibodies
Steeland, S., Vandenbroucke, R. E., & Libert, C. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.003 · Cited by 468
Synthesis, Assembly, and Applications of Hybrid Nanostructures for Biosensing
Zhang, S., Geryak, R., Geldmeier, J., Kim, S., & Tsukruk, V. V. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00088 · Cited by 340
Metadata
- Authors
- Nelson, A. L.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2010-01
- Volume
- 2
- Issue
- 1
- Pages
- 77-83
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W1994323576
- Cited by
- 463
- References
- 21
- FWCI
- 9.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.